AiCure and OncoBay Clinical Partner to Improve Oncology Clinical Trials and Patient Care

Expanded access to AI for oncology sponsors will empower actionable insights to optimize drug development and help improve patients’ quality of life

February 24th, 2021

New York, N.Y. – AiCure, an AI and data analytics company focused on improving clinical trials, and OncoBay Clinical, a full-service boutique contract research organization (CRO) specializing in the simplification of complex oncology programs, today announced a strategic partnership to provide oncology sponsors with scalable, AI-powered insights to improve patient care and optimize drug development. A subsidiary of the Moffitt Cancer Center, OncoBay will make AiCure’s proprietary AI platform available for oncology trials, providing sponsors and sites with a more holistic understanding of patient health and site optimization.

“Cancer treatment – particularly during clinical trials – is a complex experience for patients both physically and emotionally. By partnering with OncoBay, we hope increased access to technology will help improve the quality of life for these patients and make their treatment journey as simple as possible,” said Dr. Ed Ikeguchi, CEO of AiCure. “Through their own smartphones, patients are able to get much needed support without leaving their homes. Enhancing the quality of trial data collected in between clinic visits will also help sites with decision-making to create meaningful, data-driven trials.”

The oncology drug pipeline has grown by 63% since 2013, but the average success rate of oncology drugs is only 3.4%. To address this discrepancy and the unique challenges of oncology trials, particularly given the complex treatment regimens, AiCure and OncoBay aim to improve patient support and trial retention, while also providing sponsors and sites with greater visibility into patient behavior. Through AiCure’s patient engagement solution, Patient Connect, oncology sites can remotely monitor patients and use real-time communication tools to guide them through complex treatment protocols, including which medication to take and when, as well as allow direct access to a clinician. Verified patient compliance information makes pharmacokinetic data instantly more robust, and these actionable insights into trial and site performance empower sponsors to make proactive, data-driven decisions, ultimately accelerating trial timelines and lowering costs of high-quality drugs.  

“With oncology’s data landscape growing in complexity, we need to arm our sponsors with the tools to drive informed decisions that will improve study outcomes,” said Krystyna Kowalczyk, President and CEO of Oncobay Clinical. “By partnering with AiCure and leveraging their unique AI-powered insights, our sponsors will gain a deeper understanding of patient behavior through high-quality data capture and develop comprehensive views of the impact of study drug administration and compliance on other data points. We’re excited to further our overall mission of collaborating with innovative, forward-thinking companies to make a difference for our customers and their patients.”

About AiCure

AiCure is an AI and advanced data analytics company that monitors patient behavior and enables remote patient engagement in clinical trials. AiCure improves predictability of study timelines, reduces costs and accelerates timelines through remote patient engagement and assessments, including measuring digital biomarkers and real-time monitoring of patient dosing. Founded in 2010 and funded by the National Institutes of Health (NIH) and leading institutional investors, AiCure has more than 65 issued patents and works with global clients in over 30 countries. AiCure is globally recognized and is a recipient of the Scrip Award, AI 100 and Digital Health 150. For more information, please visit www.aicure.com.

About OncoBay Clinical

OncoBay Clinical is a boutique contract research organization (CRO) specializing in immuno-oncology/cell therapy, offering full- service custom-curated CRO solutions for global pharmaceutical and biotech companies looking to advance their immuno-oncology product or device. As a wholly owned, for-profit subsidiary of Moffitt Cancer Center, OncoBay embeds scientific expertise, operational excellence and integrated cell manufacturing capabilities providing true end-to-end control. Built on years of IO and cell therapy expertise, a streamlined technology framework, a highly trained site network, and a dedicated team of experienced professionals, OncoBay is committed to operational excellence from start to finish. For more information, visit Oncobay.com and follow us on Facebook, Twitter and LinkedIn.

Media Contact
Siobhan Zablocki
aicure@fleishman.com 
617-986-5784